About Us
Greenstone Biosciences is a Stanford Research Park–based biotech innovator at the nexus of regulatory change and technological advancement. Founded on the belief that NAMs—and human-relevant models—are reshaping the future of medicine, we combine:
- Expertise in NAMs: Co-founder Dr. Joseph C. Wu and his Stanford lab have led NAMs research for over 20 years, driving breakthroughs in cell-based assays and organoid systems.
- AI-Powered Discovery: Proprietary machine-learning algorithms mine complex biological data, guiding candidate selection and optimizing lead molecules.
- Translational Focus: From in-house bench science to IND-enabling studies, we advance compounds through preclinical validation toward clinical trials.
Our History
2021
Greenstone Biosciences, Inc. is established at Alexandria Center for Life Sciences, co-founded by Stanford’s Dr. Joseph C. Wu, Simon Stertzer Professor of Medicine and Radiology, and Director of the Cardiovascular Institute.
2021–2025
Built a cross-disciplinary team of Stanford, Harvard, and UCLA–trained scientists to develop hiPSC-based NAM platforms and AI pipelines.
2024
Launched first IND-ready candidates, validating our integrated NAM and AI approach with regulatory partners.
Vision
We envision a future where drug development is:
By uniting two decades of NAM expertise with next-generation AI, Greenstone Biosciences aims to make safer, more effective medicines available faster than ever before.
Join Us in Reshaping Drug Discovery
Help bring safer, more effective therapies to patients—faster. Connect with us to explore partnerships or learn more about our NAMs and AI-driven approach.
